Overall survival of transplant eligible patients with newly diagnosed multiple myeloma: comparative effectiveness analysis of modern induction regimens on outcome

Overall survival (OS) of multiple myeloma has improved remarkably over time, with the recent Intergroupe Francophone du Myelome (IFM) 2009 randomized trial reporting a 4-year OS rate of approximately 82% in patients receiving modern therapy. However, survival estimates from clinical trials may overe...

Descripción completa

Detalles Bibliográficos
Autores principales: Paquin, Ashley R., Kumar, Shaji K., Buadi, Francis K., Gertz, Morie A., Lacy, Martha Q., Dispenzieri, Angela, Dingli, David, Hwa, Lisa, Fonder, Amie, Hobbs, Miriam, Hayman, Suzanne R., Zeldenrust, Steven R., Lust, John A., Russell, Stephen J., Leung, Nelson, Kapoor, Prashant, Go, Ronald S., Lin, Yi, Gonsalves, Wilson I., Kourelis, Taxiarchis, Warsame, Rahma, Kyle, Robert A., Rajkumar, S. Vincent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6289963/
https://www.ncbi.nlm.nih.gov/pubmed/30538223
http://dx.doi.org/10.1038/s41408-018-0163-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6289963/
https://www.ncbi.nlm.nih.gov/pubmed/30538223
http://dx.doi.org/10.1038/s41408-018-0163-7

Ejemplares similares